Loading…
Ruxolitinib is an effective treatment for CALR‐positive patients with myelofibrosis
Saved in:
| Published in: | British journal of haematology 2016-06, Vol.173 (6), p.938-940 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4304-cc0a282aadf2fda6a5963cc0f4a4824ef42edccaaeaf07d95d1048b2a8673643 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4304-cc0a282aadf2fda6a5963cc0f4a4824ef42edccaaeaf07d95d1048b2a8673643 |
| container_end_page | 940 |
| container_issue | 6 |
| container_start_page | 938 |
| container_title | British journal of haematology |
| container_volume | 173 |
| creator | Guglielmelli, Paola Rotunno, Giada Bogani, Costanza Mannarelli, Carmela Giunti, Laura Provenzano, Aldesia Giglio, Sabrina Squires, Matthew Stalbovskaya, Viktoriya Gopalakrishna, Prashanth Vannucchi, Alessandro M. |
| description | |
| doi_str_mv | 10.1111/bjh.13644 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1795859185</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1795859185</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4304-cc0a282aadf2fda6a5963cc0f4a4824ef42edccaaeaf07d95d1048b2a8673643</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EoqWw4AeQl7BIazvOawkVUFAlpKqsrUliq67yInYo3fEJfCNfgtsUdngzku_R0cxF6JKSMXVvkq5XY-qHnB-hoZuBxyinx2hICIk8Sng8QGfGrAmhPgnoKRqw0Cd-TJIhel10H3Whra50irXBUGGplMysfpfYthJsKSuLVd3i6e188f351dRG79MGrHaZwRttV7jcyqJWOm1dbM7RiYLCyIvDHKHlw_1yOvPmL49PzuNl3CfcyzICLGYAuWIqhxCCJPTdp-LAY8al4kzmWQYgQZEoT4J8d0zKIA4jd64_Qte9tmnrt04aK0ptMlkUUMm6M4JGSRAHCY0Dh970aOYWNK1Uoml1Ce1WUCJ2JQpXotiX6Nirg7ZLS5n_kb-tOWDSAxtdyO3_JnH3POuVP0lmfdk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1795859185</pqid></control><display><type>article</type><title>Ruxolitinib is an effective treatment for CALR‐positive patients with myelofibrosis</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Guglielmelli, Paola ; Rotunno, Giada ; Bogani, Costanza ; Mannarelli, Carmela ; Giunti, Laura ; Provenzano, Aldesia ; Giglio, Sabrina ; Squires, Matthew ; Stalbovskaya, Viktoriya ; Gopalakrishna, Prashanth ; Vannucchi, Alessandro M.</creator><creatorcontrib>Guglielmelli, Paola ; Rotunno, Giada ; Bogani, Costanza ; Mannarelli, Carmela ; Giunti, Laura ; Provenzano, Aldesia ; Giglio, Sabrina ; Squires, Matthew ; Stalbovskaya, Viktoriya ; Gopalakrishna, Prashanth ; Vannucchi, Alessandro M. ; COMFORT-II Investigators ; the COMFORT‐II Investigators</creatorcontrib><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.13644</identifier><identifier>PMID: 26303809</identifier><language>eng</language><publisher>England</publisher><subject>CALR ; Calreticulin - genetics ; Humans ; JAK inhibitor ; myelofibrosis ; myeloproliferative neoplasm ; Primary Myelofibrosis - drug therapy ; Primary Myelofibrosis - genetics ; Primary Myelofibrosis - mortality ; Pyrazoles - administration & dosage ; Retrospective Studies ; ruxolitinib ; Splenomegaly - drug therapy ; Survival Rate ; Thrombocytosis - drug therapy ; Treatment Outcome</subject><ispartof>British journal of haematology, 2016-06, Vol.173 (6), p.938-940</ispartof><rights>2015 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4304-cc0a282aadf2fda6a5963cc0f4a4824ef42edccaaeaf07d95d1048b2a8673643</citedby><cites>FETCH-LOGICAL-c4304-cc0a282aadf2fda6a5963cc0f4a4824ef42edccaaeaf07d95d1048b2a8673643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26303809$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guglielmelli, Paola</creatorcontrib><creatorcontrib>Rotunno, Giada</creatorcontrib><creatorcontrib>Bogani, Costanza</creatorcontrib><creatorcontrib>Mannarelli, Carmela</creatorcontrib><creatorcontrib>Giunti, Laura</creatorcontrib><creatorcontrib>Provenzano, Aldesia</creatorcontrib><creatorcontrib>Giglio, Sabrina</creatorcontrib><creatorcontrib>Squires, Matthew</creatorcontrib><creatorcontrib>Stalbovskaya, Viktoriya</creatorcontrib><creatorcontrib>Gopalakrishna, Prashanth</creatorcontrib><creatorcontrib>Vannucchi, Alessandro M.</creatorcontrib><creatorcontrib>COMFORT-II Investigators</creatorcontrib><creatorcontrib>the COMFORT‐II Investigators</creatorcontrib><title>Ruxolitinib is an effective treatment for CALR‐positive patients with myelofibrosis</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><subject>CALR</subject><subject>Calreticulin - genetics</subject><subject>Humans</subject><subject>JAK inhibitor</subject><subject>myelofibrosis</subject><subject>myeloproliferative neoplasm</subject><subject>Primary Myelofibrosis - drug therapy</subject><subject>Primary Myelofibrosis - genetics</subject><subject>Primary Myelofibrosis - mortality</subject><subject>Pyrazoles - administration & dosage</subject><subject>Retrospective Studies</subject><subject>ruxolitinib</subject><subject>Splenomegaly - drug therapy</subject><subject>Survival Rate</subject><subject>Thrombocytosis - drug therapy</subject><subject>Treatment Outcome</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp1kMtOwzAQRS0EoqWw4AeQl7BIazvOawkVUFAlpKqsrUliq67yInYo3fEJfCNfgtsUdngzku_R0cxF6JKSMXVvkq5XY-qHnB-hoZuBxyinx2hICIk8Sng8QGfGrAmhPgnoKRqw0Cd-TJIhel10H3Whra50irXBUGGplMysfpfYthJsKSuLVd3i6e188f351dRG79MGrHaZwRttV7jcyqJWOm1dbM7RiYLCyIvDHKHlw_1yOvPmL49PzuNl3CfcyzICLGYAuWIqhxCCJPTdp-LAY8al4kzmWQYgQZEoT4J8d0zKIA4jd64_Qte9tmnrt04aK0ptMlkUUMm6M4JGSRAHCY0Dh970aOYWNK1Uoml1Ce1WUCJ2JQpXotiX6Nirg7ZLS5n_kb-tOWDSAxtdyO3_JnH3POuVP0lmfdk</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Guglielmelli, Paola</creator><creator>Rotunno, Giada</creator><creator>Bogani, Costanza</creator><creator>Mannarelli, Carmela</creator><creator>Giunti, Laura</creator><creator>Provenzano, Aldesia</creator><creator>Giglio, Sabrina</creator><creator>Squires, Matthew</creator><creator>Stalbovskaya, Viktoriya</creator><creator>Gopalakrishna, Prashanth</creator><creator>Vannucchi, Alessandro M.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201606</creationdate><title>Ruxolitinib is an effective treatment for CALR‐positive patients with myelofibrosis</title><author>Guglielmelli, Paola ; Rotunno, Giada ; Bogani, Costanza ; Mannarelli, Carmela ; Giunti, Laura ; Provenzano, Aldesia ; Giglio, Sabrina ; Squires, Matthew ; Stalbovskaya, Viktoriya ; Gopalakrishna, Prashanth ; Vannucchi, Alessandro M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4304-cc0a282aadf2fda6a5963cc0f4a4824ef42edccaaeaf07d95d1048b2a8673643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>CALR</topic><topic>Calreticulin - genetics</topic><topic>Humans</topic><topic>JAK inhibitor</topic><topic>myelofibrosis</topic><topic>myeloproliferative neoplasm</topic><topic>Primary Myelofibrosis - drug therapy</topic><topic>Primary Myelofibrosis - genetics</topic><topic>Primary Myelofibrosis - mortality</topic><topic>Pyrazoles - administration & dosage</topic><topic>Retrospective Studies</topic><topic>ruxolitinib</topic><topic>Splenomegaly - drug therapy</topic><topic>Survival Rate</topic><topic>Thrombocytosis - drug therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guglielmelli, Paola</creatorcontrib><creatorcontrib>Rotunno, Giada</creatorcontrib><creatorcontrib>Bogani, Costanza</creatorcontrib><creatorcontrib>Mannarelli, Carmela</creatorcontrib><creatorcontrib>Giunti, Laura</creatorcontrib><creatorcontrib>Provenzano, Aldesia</creatorcontrib><creatorcontrib>Giglio, Sabrina</creatorcontrib><creatorcontrib>Squires, Matthew</creatorcontrib><creatorcontrib>Stalbovskaya, Viktoriya</creatorcontrib><creatorcontrib>Gopalakrishna, Prashanth</creatorcontrib><creatorcontrib>Vannucchi, Alessandro M.</creatorcontrib><creatorcontrib>COMFORT-II Investigators</creatorcontrib><creatorcontrib>the COMFORT‐II Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guglielmelli, Paola</au><au>Rotunno, Giada</au><au>Bogani, Costanza</au><au>Mannarelli, Carmela</au><au>Giunti, Laura</au><au>Provenzano, Aldesia</au><au>Giglio, Sabrina</au><au>Squires, Matthew</au><au>Stalbovskaya, Viktoriya</au><au>Gopalakrishna, Prashanth</au><au>Vannucchi, Alessandro M.</au><aucorp>COMFORT-II Investigators</aucorp><aucorp>the COMFORT‐II Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ruxolitinib is an effective treatment for CALR‐positive patients with myelofibrosis</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2016-06</date><risdate>2016</risdate><volume>173</volume><issue>6</issue><spage>938</spage><epage>940</epage><pages>938-940</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><cop>England</cop><pmid>26303809</pmid><doi>10.1111/bjh.13644</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2016-06, Vol.173 (6), p.938-940 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1795859185 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | CALR Calreticulin - genetics Humans JAK inhibitor myelofibrosis myeloproliferative neoplasm Primary Myelofibrosis - drug therapy Primary Myelofibrosis - genetics Primary Myelofibrosis - mortality Pyrazoles - administration & dosage Retrospective Studies ruxolitinib Splenomegaly - drug therapy Survival Rate Thrombocytosis - drug therapy Treatment Outcome |
| title | Ruxolitinib is an effective treatment for CALR‐positive patients with myelofibrosis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T20%3A42%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ruxolitinib%20is%20an%20effective%20treatment%20for%20CALR%E2%80%90positive%20patients%20with%20myelofibrosis&rft.jtitle=British%20journal%20of%20haematology&rft.au=Guglielmelli,%20Paola&rft.aucorp=COMFORT-II%20Investigators&rft.date=2016-06&rft.volume=173&rft.issue=6&rft.spage=938&rft.epage=940&rft.pages=938-940&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.13644&rft_dat=%3Cproquest_cross%3E1795859185%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4304-cc0a282aadf2fda6a5963cc0f4a4824ef42edccaaeaf07d95d1048b2a8673643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1795859185&rft_id=info:pmid/26303809&rfr_iscdi=true |